HEK-293H cells were cotransfected with either p53 siRNA or a negative control siRNA, in combination with each reporter assay and the negative control from the Cancer 10-Pathway Reporter Array plate. 16 hours after transfection, medium was changed to complete medium. 48 hours after transfection, the dual-luciferase assay was performed. Results are expressed as fold change.

HeLa cells were reverse transfected with the Immune Response 10-Pathway Cignal Finder Reporter Array. 16 hours after transfection, medium was changed to assay medium. 32 hours after transfection, cells were treated with 5 ng/ml TNFα or left untreated. After 6 hours treatment, dual-luciferase assays were performed. Results are expressed as fold change.

HepG2 cells were reverse transfected with each reporter assay and the controls on the Stress and Toxicity 10-Pathway Reporter Array plate. 16 hours after transfection, the medium was changed to complete medium. After 30 hours, cells were treated with increasing dosages of tunicamycin (0–4 µg/ml). After 48 hours, the dual-luciferase assay was performed; results are expressed as fold change. 0.125 µg/ml Tunicamycin is the lowest effective non-toxic dose for glycoprotein synthesis inhibition.